Hudson Bay Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Hudson Bay Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.8M	Buy	465,000 +19,494	+4%	+$429K	0.03%	326
2026 Q1	$9.92M	Buy	445,506 +375,506	+536%	+$8.97M	0.03%	317
2025 Q4	$1.87M	Sell	70,000 -300	-0.4%	-$7.17K	0.01%	724
2025 Q3	$1.5M	Sell	70,300 -119,700	-63%	-$2.83M	0.01%	794
2025 Q2	$4.1M	Sell	190,000 -120,950	-39%	-$2.25M	0.01%	598
2025 Q1	$5.16M	Buy	310,950 +45,950	+17%	+$835K	0.02%	586
2024 Q4	$4.86M	Sell	265,000 -110,000	-29%	-$1.78M	0.02%	510
2024 Q3	$5.77M	Sell	375,000 -12,500	-3%	-$209K	0.02%	389
2024 Q2	$6.3M	Buy	387,500 +162,500	+72%	+$2.62M	0.03%	338
2024 Q1	$4.16M	Buy	+225,000	New	+$5.57M	0.02%	337
2023 Q2	–	Sell	-50,000	Closed	-$941K	–	839
2023 Q1	$941K	Sell	50,000 -150,000	-75%	-$2.86M	0.01%	597
2022 Q4	$3.18M	Buy	200,000 +25,000	+14%	+$391K	0.03%	487
2022 Q3	$2.86M	Sell	175,000 -105,000	-38%	-$1.7M	0.03%	628
2022 Q2	$3.94M	Buy	280,000 +260,000	+1,300%	+$4.85M	0.03%	539
2022 Q1	$484K	Sell	20,000 -25,000	-56%	-$605K	0.01%	882
2021 Q4	$1.05M	Sell	45,000 -181,000	-80%	-$3.64M	0.01%	785
2021 Q3	$3.75M	Buy	226,000 +166,000	+277%	+$3.2M	0.05%	456
2021 Q2	$1.46M	Buy	60,000 +30,000	+100%	+$677K	0.02%	671
2021 Q1	$774K	Buy	+30,000	New	+$1.32M	0.01%	705
2020 Q4	–	Sell	-30,000	Closed	-$1.24M	–	582
2020 Q3	$1.24M	Buy	+30,000	New	+$1.3M	0.02%	402
2019 Q3	–	Sell	-15,000	Closed	-$455K	–	395
2019 Q2	$401K	Hold	15,000	–	–	0.01%	358
2019 Q1	$403K	Hold	15,000	–	–	0.01%	620
2018 Q4	$243K	Sell	15,000 -25,000	-63%	-$485K	﹤0.01%	729
2018 Q3	$830K	Hold	40,000	–	–	0.01%	594
2018 Q2	$611K	Buy	+40,000	New	+$713K	0.01%	685
2017 Q2	–	Sell	-80,000	Closed	-$2.75M	–	516
2017 Q1	$2.75M	Buy	+80,000	New	+$2.82M	0.04%	394

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hudson Bay Capital Management's ACAD Position: Q2 2026 in Review

Hudson Bay Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 4.4% in Q2 2026, buying an estimated $429K and bringing the position to 465,000 shares worth $11.8M. The position accounts for 0.03% of the portfolio, ranked #326.

Hudson Bay Capital Management first reported a position in ACAD in Q1 2017 and has held it in 26 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Hudson Bay Capital Management held 465,000 shares of Acadia Pharmaceuticals worth $11.8M as of Q2 2026.
Hudson Bay Capital Management bought 19,494 Acadia Pharmaceuticals shares in Q2 2026, an estimated $429K.
Acadia Pharmaceuticals made up 0.03% of Hudson Bay Capital Management's portfolio in Q2 2026, its #326 holding.
Hudson Bay Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2017 and has held it in 26 quarters since.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.